Kisqali 200Mg Tab 63s

Kisqali 200 mg Tablets contains ribociclib, a targeted cancer therapy used to treat hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer in combination with endocrine therapy. It belongs to a class of drugs called CDK4/6 inhibitors, which slow down cancer cell growth by interfering with the cell cycle.

What is Kisqali 200 mg Tablet?

Kisqali (ribociclib) is an oral medication used in combination with hormone therapy such as letrozole or fulvestrant to manage HR-positive, HER2-negative breast cancer in postmenopausal women or premenopausal women receiving ovarian suppression therapy.

Uses of Kisqali 200 mg Tablets

• Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer
• Used in combination with aromatase inhibitors or fulvestrant
• Helps delay disease progression
• Suitable for both postmenopausal and premenopausal women (with ovarian suppression)

Benefits of Kisqali 200 mg

• Targets cancer cells by blocking CDK4/6 enzymes
• Slows tumor growth and spread
• Improves progression-free survival
• Enhances effectiveness of hormone therapy
• Convenient oral capsule regimen

How Kisqali Works

Kisqali (ribociclib) inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which are proteins that promote cell division. By blocking these enzymes, it prevents cancer cells from multiplying and helps control tumor growth.

Side Effects of Kisqali 200 mg Tablets

Common Side Effects

• Neutropenia (low white blood cells)
• Fatigue
• Nausea
• Diarrhea
• Hair thinning

Serious Side Effects

• Heart rhythm problems (QT prolongation)
• Liver enzyme abnormalities
• Severe infections due to low immunity
• Blood clots
• Rare severe lung or kidney issues

Precautions & Warnings

• Regular blood count, liver function, and ECG monitoring required
• Take exactly as prescribed; do not adjust doses on your own
• Avoid during pregnancy or breastfeeding
• Inform your doctor about any other medications to prevent interactions
• Report any signs of infection or unusual bleeding promptly

Dosage & Administration

• Typically taken once daily for 21 consecutive days, followed by 7 days off (28-day cycle)
• Take with or without food at the same time each day
• Follow your oncologist’s instructions strictly

Packaging Information

• Pack size: 63 tablets
• Designed for three 28-day treatment cycles

Conclusion

Kisqali 200 mg Tablets (63’s) is an effective targeted therapy for HR-positive, HER2-negative advanced breast cancer. Used in combination with hormonal therapy, it slows disease progression and improves patient outcomes when monitored carefully.